Affini-T Raises $175m For Bicoastal TCR Play Focused On KRAS-Mutated Solid Tumors

 
• By Joseph Haas
  
Affini-T cancer cell therapy
Affini-T plans to target KRAS mutations with TCR therapeutics • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business